source
- Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in IndiaResearchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
- Personalized vaccines show promise in extending survival for some brain cancer patients, Dana-Farber study findsPersonalized cancer vaccines are being investigated as a way to make aggressive brain tumors more responsive to immunotherapy, according to new research from the Dana-Farber Cancer Institute. The…Endpoints · 5mo agoPositive readoutPositive